Insider · CIK 0002031509
Caitlin Zulla
Files at EYE (National Vision Holdings, Inc.), LMRI (Lumexa Imaging Holdings, Inc.). First filing -, latest -.
Caitlin Zulla files SEC Form 4 as director and CEO at EYE (National Vision Holdings, Inc.), and also at LMRI (Lumexa Imaging Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Caitlin Zulla has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | LMRI Lumexa Imaging Holdings, Inc. | AGrant or award Common Stock | +64,864 | $0.00 | $0 | 64,864 | Dec 16, 2025 |
| Dec 12, 2025 | LMRI Lumexa Imaging Holdings, Inc. | AGrant or award Common Stock | +64,864 | $0.00 | $0 | 129,728 | Dec 16, 2025 |
| Jun 18, 2025 | EYE National Vision Holdings, Inc. | AGrant or award Restricted Stock Units | +10,870 | $0.00 | $0 | 21,880 | Jun 23, 2025 |
Questions about Caitlin Zulla
Answered from the filings on this page, as of the latest one.
Is Caitlin Zulla buying or selling?
Caitlin Zulla has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Caitlin Zulla's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Caitlin Zulla has 0.
Where does Caitlin Zulla file Form 4?
Caitlin Zulla has filed Form 4 at EYE (National Vision Holdings, Inc.); LMRI (Lumexa Imaging Holdings, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.